Methods and compositions for thrombolytic therapy

Abstract

Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.

What is claimed is: 
     
       1. A composition suitable for thrombolytic or fibrinolytic therapy comprising a therapeutic amount of a Factor XIIIa inhibitor compound in a pharmaceutically acceptable carrier wherein the factor XIIIa inhibitor compound is 2-(1-acetonylthio)-5-methylthiazolo(2,3-b)-1,3,4-thiadiazolium perchlorate. 
     
     
       2. A composition according to claim 1 wherein the pharmaceutically acceptable carrier is a sterile physiological medium. 
     
     
       3. A composition according to claim 1 which also contains a plasminogen activator. 
     
     
       4. A method for lysing clots in thrombotic patients which comprises intravenously administering a therapeutically effective amount of a composition comprising a Factor XIIIa inhibitor compound, said Factor XIIIa inhibitor compound being 2-(1-acetonylthio)-5-methyl-thiazolo(2,3,-b)-1,3,4-thiadiazolium perchlorate. 
     
     
       5. A method according to claim 4 wherein a plasminogen activator is also administered. 
     
     
       6. A method according to claim 5 wherein the plasminogen activator is tissue plasminogen activator. 
     
     
       7. A method according to claim 5 wherein the plasminogen activator is selected from the group consisting of tissue plasminogen activator, urokinase, prourokinase, streptokinase and eminase. 
     
     
       8. A method according to claim 4 wherein the therapeutic dose is delivered by a single, multiple or continuous intravenous administration. 
     
     
       9. A method according to claim 8 wherein the therapeutic dose is delivered by continuous infusion. 
     
     
       10. A method according to claim 4 wherein the Factor XIIIa inhibitor compound is administered first in a single bolus and the plasmingen activator then administered by continuous infusion.